Alzheimer’s drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
Related Articles
-
India’s coronavirus death toll passes 100,000 as cases continue to rise
India’s death toll from the novel coronavirus surpassed 100,000 on Saturday, only the third country in the world to...
-
Your pets can catch Covid from you, and cats appear more susceptible than dogs
Pet cats and dogs are much more likely to contract Covid-19 than their stray peers — and cats are...
-
Antibody treatments can slow hospitalizations, but vaccines are best
As the delta variant surges across the South, state and local governments are rushing to set up antibody treatment...
-
Babies with eczema could go on to develop food allergies, asthma and hay fever – in that order
Eczema in young babies could be a sign that a child will go on to develop more allergies. New...
-
What is West Nile, the virus that sent Dr. Anthony Fauci to the hospital?
Of all of the viruses that Dr. Anthony Fauci studied during his decades serving as the head of the...
-
CDC shortens 14-day quarantine recommendation to 7 to 10 days
The Centers for Disease Control and Prevention is shortening the recommended quarantine period from 14 days after a person...
-
Feeling angry may help people achieve their goals, study finds
If you want to achieve your goals, get angry. New research indicates that anger can help people overcome challenges...
-
After FDA approval of Pfizer vaccine, several steps still left before kids under 12 can be vaccinated
The Food and Drug Administration’s decision to grant full approval to Pfizer-BioNTech’s two-dose Covid-19 vaccine Monday for people ages...
Recent Comments